Moderna, Inc. $MRNA Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA decreased its holdings in Moderna, Inc. (NASDAQ:MRNA) by 25.9% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 446,265 shares of the company’s stock after selling 156,247 shares during the period. Pictet Asset Management Holding SA’s holdings in Moderna were worth $89,131,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. Parallel Advisors LLC grew its stake in shares of Moderna by 8.8% during the third quarter. Parallel Advisors LLC now owns 5,082 shares of the company’s stock worth $979,000 after acquiring an additional 410 shares during the last quarter. Abacus Wealth Partners LLC purchased a new position in shares of Moderna during the third quarter worth $259,000. Plancorp LLC acquired a new position in Moderna during the third quarter valued at $210,000. May Hill Capital LLC acquired a new position in Moderna during the third quarter valued at $238,000. Finally, Heritage Family Offices LLP purchased a new stake in Moderna in the third quarter valued at $253,000. Institutional investors own 75.33% of the company’s stock.

Insider Activity

In related news, CFO James M. Mock sold 34,836 shares of the business’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $134.49, for a total value of $4,685,093.64. Following the completion of the sale, the chief financial officer owned 59,375 shares of the company’s stock, valued at approximately $7,985,343.75. The trade was a 36.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 40,294 shares of the company’s stock in a transaction on Monday, September 14th. The stock was sold at an average price of $144.13, for a total transaction of $5,807,574.22. Following the transaction, the president owned 1,525,858 shares of the company’s stock, valued at $219,921,913.54. This represents a 2.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 197,251 shares of company stock worth $33,875,904 in the last quarter. Corporate insiders own 10.80% of the company’s stock.

Moderna Stock Performance

Shares of MRNA stock opened at $269.00 on Tuesday. The company has a market capitalization of $107.40 billion, a P/E ratio of -37.89 and a beta of 1.16. The business’s 50 day moving average is $194.47 and its two-hundred day moving average is $92.61. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $280.80.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Friday, November 6th. The company reported $0.38 EPS for the quarter, beating analysts’ consensus estimates of ($1.10) by $1.48. The business had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $890.25 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. The business’s revenue was up 29.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.51) earnings per share. Analysts expect that Moderna, Inc. will post -6.11 EPS for the current fiscal year.

Key Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Raised outlook and improved results: Moderna lifted its 2026 revenue-growth forecast to 15%–25% after a Q3 beat, citing lower costs and gains from respiratory vaccines. Moderna Q3 Earnings Call Highlights Raised Outlook and Oncology
• Positive Sentiment: Oncology pipeline milestone: Phase 3 data for personalized cancer therapy intismeran showed a 42% reduction in melanoma recurrence or death risk. Moderna aims to file with the FDA by year-end 2026, potentially setting up a decision in 2027. Can Moderna’s First Cancer Therapy Win FDA Approval in 2027?
• Positive Sentiment: Moderna’s collaboration with Tempus AI is among partnerships expected to generate about $192.5 million over five years, adding a potential source of revenue beyond vaccine sales. The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom
• Neutral Sentiment: Analysts raised one fair-value estimate from $135.84 to $145.42, reflecting improved Q3 execution and intismeran’s potential, while noting uncertainty about future COVID and oncology revenue. Moderna Stock Fair Value Rises After Intismeran Data And Q3 Beat
• Negative Sentiment: Revenue concentration and valuation risk: Nearly all revenue still comes from COVID-related products, leaving Moderna exposed to demand changes. Goldman Sachs raised its target to $195 but kept a neutral rating; that target and the cited fair-value estimate are both below the $269 price in the provided market data. Moderna’s Q3 Numbers May Have Seemed Impressive, but They Aren’t Enough to Make the Stock a Buy

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on MRNA shares. Argus raised Moderna from a “hold” rating to a “buy” rating and set a $180.00 price target on the stock in a research report on Friday, August 28th. Piper Sandler restated an “overweight” rating and issued a $305.00 target price (up from $230.00) on shares of Moderna in a research note on Monday. Bradesco Corretora raised Moderna to an “outperform” rating in a report on Friday, August 28th. Deutsche Bank Aktiengesellschaft initiated coverage on Moderna in a research report on Friday, August 28th. They set a “hold” rating and a $125.00 price target for the company. Finally, Loop Capital set a $135.00 price target on Moderna in a report on Wednesday, August 19th. Six research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $113.75.

About Moderna

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease.

The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases.

Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.